Lung cancer (non-small cell)
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
Where to go
1 hospital in India taking patients for this trial.
Registry summary (technical)
The purpose of this study is to compare the clinical benefit of the combination of Navlimetostat (BMS-986504) (a selective MTA-cooperative inhibitor of PRMT5) plus pembrolizumab and chemotherapy versus placebo plus pembrolizumab and chemotherapy in first-line metastatic non-small cell lung cancer participants with homozygous MTAP deletion
Sponsor: Bristol-Myers Squibb
NCT07063745 on ClinicalTrials.gov
Last updated on the registry 23 Sep 2026 · read by us 20 Oct 2026